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Abstract
Background
Pancreatic ductal adenocarcinoma (PDAC) is a highly desmoplastic tumor with a dismal
prognosis for most patients. Fibrosis and inflammation are hallmarks of tumor desmoplasia.
We have previously demonstrated that preventing the activation of pancreatic stellate cells
(PSCs) and alleviating desmoplasia are beneficial strategies in treating PDAC. Metformin is
a widely used glucose-lowering drug. It is also frequently prescribed to diabetic pancreatic
cancer patients and has been shown to associate with a better outcome. However, the
underlying mechanisms of this benefit remain unclear. Metformin has been found to modu-
late the activity of stellate cells in other disease settings. In this study, we examine the effect
of metformin on PSC activity, fibrosis and inflammation in PDACs.
Methods/Results
In overweight, diabetic PDAC patients and pre-clinical mouse models, treatment with met-
formin reduced levels of tumor extracellular matrix (ECM) components, in particular hyaluro-
nan (HA). In vitro, we found that metformin reduced TGF-ß signaling and the production of
HA and collagen-I in cultured PSCs. Furthermore, we found that metformin alleviates tumor
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inflammation by reducing the expression of inflammatory cytokines including IL-1β as well
as infiltration and M2 polarization of tumor-associated macrophages (TAMs) in vitro and in
vivo. These effects on macrophages in vitro appear to be associated with a modulation of
the AMPK/STAT3 pathway by metformin. Finally, we found in our preclinical models that
the alleviation of desmoplasia by metformin was associated with a reduction in ECM remod-
eling, epithelial-to-mesenchymal transition (EMT) and ultimately systemic metastasis.
Conclusion
Metformin alleviates the fibro-inflammatory microenvironment in obese/diabetic individuals
with pancreatic cancer by reprogramming PSCs and TAMs, which correlates with reduced
disease progression. Metformin should be tested/explored as part of the treatment strategy
in overweight diabetic PDAC patients.
Introduction
The prognosis for patients with pancreatic cancer is dismal, with an overall five-year rate sur-
vival of 7% [1]. Obesity and type-2 diabetes mellitus (DM2) have become a pandemic world-
wide [2, 3]. Recent studies have demonstrated that these metabolic abnormalities are
associated with the increased incidence, progression and poor prognosis of PDAC [4–9]. At
diagnosis, approximately half of PDAC patients are overweight or obese, and up to 80% of
patients present with diabetes or glucose intolerance [10–17]. DM2 and obesity may promote
PDAC through pro-tumorigenic insulin and insulin-like growth factor-1 (IGF-1) [18–20] as
well as chronic inflammation [21, 22]. Hence, pharmacological interventions that target diabe-
tes/obesity may also produce anti-tumor effects. One such agent, currently under intense inves-
tigation, is metformin, the most widely prescribed anti-diabetic generic drug that is also
frequently administered to diabetic PDAC patients [23]. Metformin has been shown to
improve treatment outcomes in preclinical models of PDAC [24–30]. In addition, it reduces
the incidence of pancreatic cancer in diabetic patients as well as improves survival (reduced
risk of death by 32%) in newly diagnosed cases [31–33]. However, the mechanisms of action of
metformin in pancreatic cancer are not well understood. In vitro studies have addressed the
impact of metformin on transcription factors, microRNAs, DNA damage, cancer stem cells
and metabolism [34–38]. In addition, metformin has been shown to modulate the function of
hepatic stellate cells, reduce oxidative stress in cancer-associated fibroblasts, and decrease
tumor inflammation [34, 35, 39, 40]. We and others have shown that reprogramming PSCs
reduces the production of extracellular matrix (ECM) components such as collagen-I and hya-
luronan (HA), and slows the progression of pancreatic cancer [41–45]. However, the impact of
metformin on PSC activation, production of ECM components and tumor desmoplasia has
never been described.
The aim of this study is to elucidate the functional mechanisms of metformin within the
PDAC fibro-inflammatory tumor microenvironment. In vivo studies of pancreatic cancers to
date have been mainly performed in xenograft models in normal weight/non-diabetic mice
where metformin has been shown to be less effective [26, 46–48]. Hence, we used two immuno-
competent syngeneic mouse models that closely mimic obesity / DM2, to better represent pan-
creatic cancer patients—the majority of pancreatic cancer patients present with either new onset
DM2 or impaired glucose tolerance at the time of diagnosis [10–17]—and the target population
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of metformin. Furthermore, we complemented our mouse models with in vitro studies as well as
with analysis of human samples of pancreatic cancer from normal weight and overweight/obese
patients. We found that metformin directly reprograms PSCs and TAMs and alleviates fibrosis
and inflammation in obese/diabetic models of PDAC. These effects of metformin correlated
with reduced ECM remodeling and epithelial-to-mesenchymal transition (EMT), ultimately
affecting metastasis. We confirmed that ECM levels in human PDAC samples in overweight and
obese patients were indeed lower in the patient population treated with metformin.
Materials and Methods
Animal experiments
The Institutional Animal Care and Use Committee of the Massachusetts General Hospital
approved all experimental use of animals in this study. All animal procedures followed Public
Health Service Policy on Humane Care of Laboratory Animals guidelines. Wild-type (WT)
C57BL/6 and FVB male mice were originally obtained from The Jackson Laboratory (The Jack-
son Laboratory, Bar Harbor, Maine) and bred and maintained in our defined-flora animal
facility. Mice were maintained on a 12-h light-dark cycle in a temperature-controlled barrier
facility, with ad libitum access to food and acidified water. To generate obese/diabetic mouse
models, mice (6-weeks old) were given a 60% fat diet (D12492, Research Diets, New Bruns-
wick, NJ) for 10 weeks as previously described [49–51] (time of tumor implantation) and con-
tinued for the duration of tumor studies. For tumor experiments, the PAN02 and AK4.4
syngeneic PDAC models were used in C57BL/6 and FVB immunocompetent mice, respec-
tively. PAN02 cells (SMAD4-m174) [52] were obtained from ATCC. AK4.4 cells (KrasG12D
and p53+/-) were kindly provided by Dr. Nabeel Bardeesy at MGH. These cells were isolated
from mice generating spontaneous pancreatic tumors (Ptf1-Cre/LSL-KrasG12D/p53Lox/+) [53].
Orthotopic pancreatic tumors were generated by implanting a small piece (1 mm3) of viable
tumor tissue (from a source tumor in a separate donor animal) into the pancreas of male lean
or obese FVB (AK4.4 model) or C57BL/6 (PAN02 model) mouse. Both tumor models used
were authenticated by IDEXX Laboratories. (PAN02: IDEXX RADIL Case # 22366–2013.
AK4.4: IDEXX RADIL Case # 27818–2014).
Pancreatic tumor growth studies
At 7 days post implantation, mice bearing orthotopic PAN02 or AK4.4 pancreatic tumors were
randomized into control or metformin treatment groups. At day 21, plasma and tumor sam-
ples were collected, and tumors were weighed and processed for further analysis.
Metformin treatment
The standard dose of metformin for treating humans is 1000 to 2500 mg, usually given twice
daily. In the present study, metformin was administered at 300 mg/kg in drinking water. This
can be translated to the human equivalent dose by using the Reagan-Shaw method [54].
According to the formula for the human equivalent dose [(mg/kg) = animal dose (mg/kg) x
animal (km)/ human (km). Km for a 60 kg human adults equals 37 and for a 20 g mouse equals
3], the human equivalent of murine dose of 300 mg/kg is 1459 mg for an average sized 60 kg
adult human. Therefore, the selected dose in the present study is within the safe therapeutic
range recorded in humans. Furthermore, the present study determined the therapeutic period
to be 2 weeks to evaluate the antitumor effect of metformin. This was compatible with the ther-
apeutic periods reported in previous studies [55, 56]. Fresh metformin was administered in
drinking water every 3 days. The amount added to each animal cage was calculated based on
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the average daily water intake for that cage during a period of 2 weeks prior to treatment initia-
tion, and adjusted every three days based on water consumption and body weight of the ani-
mals. The approximate plasma concentration of metformin in patients with type 2 diabetes
taking this drug is 0.05 mM, although it may accumulate in tissues and reach higher concentra-
tions locally [35]. For in vitro experiments, a range of concentration from 0.05 to 25 mM
depending on the cell line used (please see below for more details).
Effect of metformin on PSCs and macrophages in vitro
Standard MTT assays were performed on PSCs and macrophages treated with metformin in a
range of 0.05-25mM, to examine the potential effects on cell viability. RAW 264.7 (mouse leu-
kemic monocyte-macrophages) were obtained from ATCC and used to assess the effect of met-
formin on macrophages in vitro. Cells were seeded in 10 cm2 petri dishes in serum/serum-free
media and treated with metformin for 48h at concentrations ranging from 0.05 to 0.4 mM
(concentrations that do not substantially affect cell viability). Following treatment, cells were
collected for RNA and protein extraction in order to perform subsequent analysis of gene
expression of cytokines and polarization markers, and for analysis of signaling and metabolic
pathways. Human PSCs were seeded in 10 cm2 petri dishes in media with 2.5% serum and
treated with metformin for 48h at concentrations ranging from 0.1 to 10 mM. Cells were col-
lected for protein extraction for analysis of the activation of fibrosis-related pathways. Addi-
tionally, PSCs were seeded in an 8-well chamber slide (20,000 cells/well), treated with
metformin (1 mM, a concentration that does not affect cell viability) for 48h, and immunofluo-
rescent staining was performed following standard protocols. The cells were fixed with 4%
paraformaldehyde and blocked with 5% normal donkey serum for 1 h. They were incubated
with the designated primary antibodies overnight at 4°C then for 2h with the appropriate sec-
ondary antibodies at RT. PBS was used for all washes, and the stained samples were mounted
with Prolong Gold with DAPI. Images were acquired using a confocal microscope. The anti-
bodies used and image acquisition settings are described below. Both cell types were grown in
Dulbecco's modified Eagle's medium (Sigma, St. Louis, MO) supplemented with 5% (v/v) heat-
inactivated fetal bovine serum (FBS; Sigma), 100 units/ml penicillin and streptomycin. Cells
were cultured at 37°C in a humidified atmosphere including 5% CO2.
Human samples
Human samples of pancreatic cancer were obtained from the MGH tissue repository (http://
www.massgeneral.org/research/resourcelab.aspx?id=31) under an active IRB protocol (Partners
Healthcare IRB approval number: 2013P001969). Written informed consent from the donor or
the next of kin was obtained for the use of these samples for research purposes. Tumors selected
received no prior chemotherapy or radiation therapy before the surgical specimen was collected
at the time of tumor resection. A total of 28 samples were randomly selected from this subset of
samples. Body mass index was obtained for the respective sample. 7 of the samples (25%) corre-
spond to patients that were medicated with metformin at the time of resection. Paraffin sections
were stained for collagen-I and HA as described below. Images were acquired using confocal
microscopy and quantified using Matlab. Data were analyzed anonymously.
Gene Expression
Immediately following excision, tumor tissue was snap-frozen and stored in liquid nitrogen.
Total RNA was extracted and relative gene expression of macrophage M1/M2 markers was
determined using a Sybr-green based standard protocol. In addition, total RNA was extracted,
and relative gene expression was determined using RT2 Profiler PCR Arrays system (Qiagen)
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on a Stratagene Mx3000P QPCR System using pre-made pathway-focused arrays (“Fibrosis”—
Cat. Number: PAMM011Z; “Epithelial to Mesenchymal Transition (EMT)”—Cat. Number:
PAMM090Z; “TGF-ß signaling targets”—PAMM235Z; “Extracellular Matrix & Adhesion Mol-
ecules”—Cat. Number: PAMM013Z; and “Common cytokines “—Cat. Number: PAMM021Z).
Protein Expression
Western blot analysis. Each tumor sample was homogenized directly in lysis buffer for pro-
tein extraction. 20ug of denatured protein per sample was loaded on 7%, 10%, and 12% SDS-
polyacrylamide gels. Antibodies used: phospho-p38 MAPKT180/Y182 and p38; phospho-JNK
(SAPK/JNK)Thr183/Tyr185 and JNK; phospho-AKTSer473 and AKT, phospho-ERK(p44/42
MAPK)T202/Y204 and ERK; phospho-NF-κBSer536 and NK-κB; p65Ser536; phospho-Smad2Ser465/467
and Smad2; phospho-IGF-I Receptor ßTyr1135 and IGF; Phospho-IRS-1Ser612 and IRS; IR;
phpspho-stat3Tyr705 and stat3; Phospho-AMPKαThr172 and Ampkα; phospho-AmpkβSer108 and
Ampk; phospho-ACCSer79 and ACC; Phospho-PDGF Receptor ßTyr751 and PDGF Receptor ß
and snail, e-cadherin and vimentin, TGF-ß, ß-catenin, twist, LC3B. All antibodies listed above
were obtained from Cell Signaling Technology (Beverly, MA), and diluted 1:1000 with the
exception of phospho-JNK (SAPK/JNK)Thr183/Tyr185, Phospho-NF-κB p65Ser536, phospho-
Smad2Ser465/467, phospho-IGF-I Receptor ß Tyr1135, Cleaved caspase-3, Phospho-IRS-1Ser612.
Other antibodies used were: αSMA and phospho-Insulin ReceptorY972 (1:1000 and 1:500,
Abcam, MA); col-1 (1:1000); MMP-9 andMMP-2 (1:500 and 1:200, EMDMillipore-Billerica,
MA), AT1 (1:1000, LifeSpan BioSciences Inc, WA), ZEB1 (1:1000, Novus Biologicals, CO), and
ß-actin (1:5000, Sigma, MO). Quantification of protein expression relative to total receptor or
ß-actin was obtained using Image J software.
Multiplex array. Each tumor sample was homogenized directly in lysis buffer for protein
extraction. 2ug/ul of sample was used. A multiplex inflammatory multiple cytokines protein
array was used (V-PLEX Proinflammatory Panel1 mouse kit, Cat. Number: K15048D) for
ELISA analysis.
Immunofluorescence/Immunohistochemistry
For analysis of frozen sections of mouse tumor tissues, the tumors were excised and frozen in
optimal cutting temperature compound (Tissue-Tek). Transverse tumor sections, 10 μm thick,
were immunostained with specific antibodies. To obtain mosaic images of tumor sections, an
Olympus FV1000 confocal laser-scanning microscope was used. A 10x air objective acquired
1260-μm square tiles, and an automated stage scanned throughout the entire cross-section of
tumor tissue. The imaged tiles were stitched into a final mosaic image using Olympus software.
Antigen expression was quantified by measuring the area occupied by the stain of interest nor-
malized by the area of DAPI-stained nuclei (i.e., unitless), and analyzed using a custom algo-
rithm in MATLAB (The MathWorks). Identical settings and thresholds for analysis were used
for all tumors. Antibodies used for immunofluorescence were the following: Collagen-I [LF-68
antibody, 1:50 dilution, provided by Dr Larry Fisher (NIDCR)]; Hyaluronan (biotinylated hya-
luronan proteoglycan fragment, 385911, Calbiochem, 1:200 dilution); αSMA (C6198 antibody,
Sigma, 1:500 dilution); and F4/80 (MCA497A488 antibody, ABDserotec, 1:200 dilution). Cy3-,
Cy5- or FITC-conjugated secondary antibodies were used for the detection of signals by confo-
cal microscopy. Slides were counterstained with DAPI for nuclear staining.
MMP activity assay
Each tumor sample was homogenized directly in lysis buffer for protein extraction. A standard
commercial assay (Abcam ab112146) was used to detect the general activity of MMPs in the
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tumor samples. Tumor lysates were incubated with a fluorescent substrate [fluorescence reso-
nance energy transfer (FRET) peptide] for 1, 2, and 16 hours, and fluorescence was measured
using a fluorescent microplate reader.
Flow Cytometry
Tumor-bearing mice were perfused through intracardiac injection of PBS and sacrificed. Pan-
creatic tumor tissues were harvested, minced, and digested at 37°C for 1 h with DMEM con-
taining collagenase type 1A (1.5 mg/mL), hyaluronidase (1.5 mg/mL), and DNase (2 ug/mL).
The digestion mixtures were filtered through 70-μm cell strainers. Single-cell suspensions were
incubated with rat anti-mouse CD16/CD32 mAb for blocking and stained with fluorochrome-
conjugated antibodies in cold buffer (1% BSA, 0.1% NaN3 in PBS). 7-amino-actinomycin D
(7AAD) reagent (eBioscience) was added to the stained tubes per manufacturer’s instruction
immediately before running the flow analysis. Flow cytometry data were acquired on an LSRII
flow cytometer (Becton Dickinson) and were analyzed with FACSDiva software. FSC-A vs.
FSC-W and SSC-A vs. SSC-W were applied to discriminate the doublet/aggregated events. The
following monoclonal anti-mouse antibodies were used: CD45-PE, CD45-PE-Cy7,
CD45-FITC, CD11b-APC-Cy7, CD11b-APC, F4/80-APC (BD Biosciences) and F4/80-FITC
and F4/80-PE (eBioscience).
Macrophage isolation
After cutting the tumor tissue into pieces 0.5 mm in diameter, tumors were dissociated with
collagenase and hyaluronidase for one hour. Dissociated tumors were washed with sorting
buffer (0.5% BSA in PBS) and passed through cell strainers before they were blocked using Fcr
and subsequently incubated with a F4/80 biotinylated primary antibody (eBiosciences) for 15
min. Anti-biotin conjugated magnetic beads (Miltenyl Biotech) were added to the cell suspen-
sion and incubated for 15 min before exposing the cells to magnetic columns (MACS LS-col-
umns fromMiltenyl Biotech) for cell separation.
Statistical analysis
Statistical differences between groups were assessed by a two-tailed Student t-test. Two-way
analysis of variance was used when comparing body weight over time between the control and
metformin-treated groups. The incidence of metastasis and wall invasion was analyzed using
chi-square. All statistical analyzes were performed using Prism Graphpad software. All results
were considered statistically significant when the P value was less than 0.05 when calculated
with the appropriate statistical test. Results are presented as the mean ± standard error.
Results
Metformin reduces desmoplasia in mouse and human PDACs
We have shown that the reduction of desmoplasia—lowering ECM components such as HA
and collagen-I—in PDACs potentiate anti-tumor treatments [41–43]. Hence, we examined the
relationship between metformin treatment and desmoplasia in PDACs in chemo/radiotherapy
naïve PDAC surgical samples. We found that in overweight or obese patients under treatment
with metformin, levels of HA were 30% lower than in patients not taking metformin (Fig 1i
and 1ii). Interestingly, no difference in HA levels was observed in metformin treated patients
of normal weight. On the other hand, treatment with metformin appeared to have no impact
on collagen-I expression in either body weight group (S1 Fig).
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To evaluate if we could recapitulate these findings in pre-clinical models, we used FVB and
C57BL/6 mice fed with a high-fat diet. We, along with others have shown that a high-fat diet
induces obesity and metabolic abnormalities typical of DM2, elevated glucose, insulin and
IGF-1 [50, 57–60] in these strains. After 10 weeks on the high-fat diet, AK4.4 and PAN02
tumors were orthotopically implanted in obese FVB and C57BL/6 mice, respectively. The ani-
mals were randomly assigned to metformin in drinking water (300 mg/Kg) or no treatment at
day 7 until day 21 when plasma and tumors were collected. Treatment with metformin corre-
lated with reduced expression of HA by 64% (Fig 2Ai and 2Aii) and of collagen-I by 35% (Fig
2Ai and 2Aiii) in AK4.4. tumors. Furthermore, the percentage of activated PSCs (as deter-
mined by the expression of alpha-smooth muscle antigen, αSMA) that co-express HA and col-
lagen-I decreased by 58 and 38%, respectively (Fig 2Bi–2Biii). In a second, less desmoplastic
model (PAN02), metformin decreased the expression of HA by 40% and of collagen-I by 22%,
although it did not reach statistical significance (S2i–S2iii Fig). Nonetheless, metformin signifi-
cantly reduced the density of collagen-I positive activated PSCs in tumors by 54% in this model
(S2v Fig). The density of HA positive activated PSCs in PAN02 tumors was also reduced by
57% (S2iv Fig) but did not reach significance. We have shown previously that Angiotensin-II
receptor 1 (AT1) is critical for HA and collagen-I production in PDACs [43]. Indeed, we
observed that metformin was able to reduce the expression of AT1 (Fig 2C). Taken together,
these data indicate that metformin reduces desmoplasia in PDACs in overweight/obese hosts.
Metformin affects desmoplasia by directly reducing TGF-β signaling and
production of collagen-I/HA by PSCs
Collagen-I and HA are essentially produced by activated PSCs in PDACs [43, 61]. To deter-
mine if metformin treatment can directly reduce collagen-I/HA expression in PSCs, we incu-
bated PSCs in vitro with metformin. We found that, at a dose (1 mM) that does not
substantially affect the viability of PSCs (S3 Fig), metformin decreased the expression of HA
and collagen-I (Fig 3Ai–3Aiii). This indicates metformin acts on PSCs to reduce the
Fig 1. Metformin treatment associates with reduced hyaluronan levels in human pancreatic cancers in overweight/obese patients. (i)
Representative histology images showing the effect of metformin on tumor hyaluronan levels in normal weight [Body mass index (BMI)<25)] or overweight/
obese patients (BMI>25) (n = 22 controls, 7 metformin). (ii) Immunohistochemical analysis of total tumor hyaluronan levels. Metformin decreases the
hyaluronan-positive area fraction (%) in overweight/obese patients. Data are presented as the mean ± standard error. * p < 0.05 vs. control in patients with
BMI >25.
doi:10.1371/journal.pone.0141392.g001
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Fig 2. Metformin reduces ECM and AT1 expression in AK4.4 pancreatic cancer model in overweight/
obesemice. After 10 weeks of high-fat diet, AK4.4 tumors were orthotopically implanted in obese FVBmice.
Animals were randomly assigned to metformin in drinking water (300 mg/kg) or no treatment at day 7 until day
21 when tumors were collected. (A-i) Representative immunohistochemistry images showing the effect of
metformin on tumor hyaluronan and collagen-I levels in AK4.4 tumors (n = 3–4). (A-ii) Quantification of
Metformin Alleviates Desmoplasia in Pancreatic Cancer
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production of these critical ECM components. Furthermore, we found that metformin (0.1-
1mM) reduced expression of AT1, TGF-β and downstream signaling via SMAD-2, as well as
PDGF-β, all key players in ECM production by PSCs (Fig 3B). In addition, metformin also
affected the activation of canonical signaling pathways that promote PSC activation and fibro-
sis [62], in particular ERK, p38, and STAT3, although at relatively higher doses (1–10 mM)
(Fig 3B). Importantly, in whole tumors, metformin decreased activation of STAT3 in both
models, with a trend for reduced p38 activation in PAN02 (S4i–S4iii Fig), suggesting that met-
formin can accumulate at concentrations high enough to affect these signaling pathways in
vivo. Taken together, these data indicate that metformin affects desmoplasia by directly reduc-
ing AT1/TGF-β/STAT3 signaling and production of collagen-I/HA by PSCs.
Metformin also improves desmoplasia by preventing recruitment and M2
polarization of macrophages in PDACs
The inflammation that occurs in PDACs is a major component of desmoplasia [63]. In particu-
lar, tumor-associated macrophages (TAMs) are a major source of cytokines that aggravate des-
moplasia in PDACs [64] and negatively affect disease outcome [65]. Therefore, we determined
here the effect of metformin on TAM infiltration in tumors. We found that TAM levels were
60% lower with metformin treatment in the AK4.4 model (Fig 4A). They also tended to be
lower (~30%, not significant) in the PAN02 model (S5A Fig). To determine a direct effect of
metformin on macrophages, we incubated macrophages with metformin in vitro for 48h at
increasing concentrations. We found that metformin affected the viability of macrophages at
doses of 0.4 mM or higher (S6 Fig). Metformin at a concentration of 0.05 mM (similar to the
concentration measured in plasma of patients taking metformin) reduced M2 markers such as
Arg-1 and IL-10, while metformin at doses higher than 0.2 mM reduced both M1 and M2
markers (Fig 4B). In flow-sorted TAMs from PAN02 tumors in vivo, we indeed confirmed an
effect of metformin on the expression of M2 markers Arg-1 (~1/2) and IL-10 (~2/3) without
significantly affecting the expression of M1 markers (Fig 4C). We then sought to understand
how metformin affects these cells. Several canonical and non-canonical signaling pathways can
be activated in PDACs during inflammation and promote expression of M2 markers on TAMs
[66–69]. Consistent with the effects on TAMs, metformin reduced activation of STAT3, JNK,
AKT and p38 in macrophages in vitro at concentrations lower than 0.2 mM (Fig 4D). As men-
tioned above, in whole tumors metformin decreased activation of STAT3 in both models, with
a trend for reduced activation of p38 in PAN02, in line with our in vitro results (S4i–S4iii Fig).
It has been shown that STAT3 activity is decreased by metformin via activation of metabolic
energy sensor AMP-activated protein kinase (AMPK) in multiple cell types [70]. Indeed, we
found that the inhibitory effects of metformin on STAT3 signaling in macrophages in vitro
associated with activation of AMPKα and downstream enzyme Acetyl-CoA Carboxylase
(ACC) (the latter evident only in serum added media) in these cells (Fig 4D and S7 Fig). Taken
hyaluronan expression in AK4.4 tumors. Metformin decreases the hyaluronan-positive area fraction (%). (A-
iii) Quantification of collagen-I expression in AK4.4 tumors. Metformin decreases the collagen-I-positive area
fraction (%). (B-i) Representative immunohistochemistry images showing the effect of metformin on
expression (co-localization) of hyaluronan and collagen-I levels in activated (αSMA-positive) pancreatic
stellate cells (PSCs) in AK4.4 tumors (n = 3–4). (B-ii) Quantification of hyaluronan expression in PSCs.
Metformin decreases the percentage of activated PSCs expressing hyaluronan. (B-iii) Quantification of
collagen-I expression in PSCs. Metformin decreases the percentage of activated PSCs expressing collagen-
I. (C-i) Representative Western blots for angiotensin-II receptor-1 (AT1) expression in AK4.4 tumors. ß-actin
is used as a control for protein loading. (C-ii) Densitometric analysis of AT1 expression normalized to ß-actin.
Metformin decreases the expression of AT1. Data are presented as the mean ± standard error. * p < 0.05 vs.
control.
doi:10.1371/journal.pone.0141392.g002
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together, these data indicate that metformin reduces TAM infiltration as well as expression of
M2 markers, which may be mediated at least in part via AMPK/STAT3 signaling inhibition in
macrophages. In addition, inflammation in tumors is characterized by an excess of inflamma-
tory cytokines that promote desmoplasia, and metformin has been shown to affect multiple
inflammatory mediators [34, 35]. Here, we found that metformin reduced the expression of IL-
1β and CXCL1 in AK4.4 tumors (Fig 4E). A reduction of IL-1β after metformin treatment also
occurred in the PAN02 tumor model (S5Bi and S5Bii Fig). In addition, a broader panel of
Fig 3. Metformin reduces collagen-I/hyaluronan production by pancreatic stellate cells. (A) PSCs were incubated in vitro with metformin (1 mM) for
48h. (A-i) Representative immunocytochemistry images showing the effect of metformin on tumor hyaluronan and collagen-I levels in human pancreatic
stellate cells (PSCs) in vitro (n = 2). (A-ii) Quantification of hyaluronan expression in PSCs. Metformin decreases the expression of hyaluronan in PSCs. (A-iii)
Quantification of the expression of collagen-I in PSCs. Metformin decreases the expression of collagen-I in PSCs. αSMA denotes activated PSCs. (B)
Representative Western blots for the expression of fibrosis-related markers and signaling proteins in PSCs treated with metformin at 0, 0.1, 1 and 10mM.
Metformin decreases the expression of fibrosis-related markers and signaling proteins in PSCs. Densitometric analysis of protein expression normalized to
ß-actin or total protein (in the case of phosphorylated proteins) is depicted as numbers below the representative bands. Data in A are presented as the
mean ± standard error. *p < 0.05 vs. control.
doi:10.1371/journal.pone.0141392.g003
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Fig 4. Metformin reprograms TAMs and reduces inflammation in tumors. (A-i) Representative immunocytochemistry images showing the effect of
metformin metformin on the expression of F4/80 (immunofluorescence) in AK4.4 tumors (percentage of viable tumor area) (n = 4). (A-ii) Metformin-treated
tumors (300 mg/kg in drinking water) had significantly reduced levels of F4/80-positive tumor-associated macrophages (TAMs). (B) Effect of metformin (0–
0.2mM) on the gene expression (qPCR) of M1 (i) and M2 (ii) markers in RAW 264.7 cells (mouse leukaemic monocyte-macrophages) in vitro. Clinically
relevant doses (0.05 mM) of metformin treatment reduces expression of M2 markers in macrophages in vitro, including Arg-1 and IL-10. (C) Effect of
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inflammation-related genes in AK4.4 tumors revealed that metformin reduced multiple genes
involved in TAM recruitment and function (S5C Fig). In conclusion, we found that metformin
reduces the production of desmoplastic cytokines (e.g., IL-1β) as well as infiltration and M2
polarization of TAMs, which may be mediated at least in part via AMPK/STAT3 signaling
inhibition in macrophages.
Metformin reduces ECM remodeling, EMT, and metastasis
In addition to producing ECM components, PSCs also promote ECM remodeling and EMT to
facilitate invasion and metastasis [43, 71, 72]. Hence, we determined whether the effects on
PSCs by metformin also extend to these processes. Indeed, metformin reduced the expression
in AK4.4 tumors of multiple genes involved in ECM remodeling (including MMPs) and EMT
(Fig 5A). In addition, metformin treatment unregulated genes that prevent ECM remodeling
(Fig 5A). Though to a lesser extent, similar findings were observed in PAN02 tumors (S8A
Fig). At the protein level, we also observed a reduction of metalloproteinase 9 (MMP-9, Fig 5Bi
and 5Bii) by 70% in the AK4.4 model with metformin treatment. Average MMP-2 levels were
also approximately half (not significant) in metformin-treated PAN02 tumors (S8Bi and S8Bii
Fig). Consistently, we confirmed in vitro that metformin decreased protein levels of MMP9 in
PSCs (S8C Fig). Furthermore, MMP activity in tumors was also decreased in metformin-
treated animals compared to control mice (Fig 5C). In addition to ECM remodeling, EMT was
also affected. At the protein expression level, the EMT marker vimentin was decreased and E-
cadherin was increased in AK4.4 with similar trends in the PAN02 model, confirming reduced
EMT (Fig 5Bi and 5Bii, S8Bi and S8Bii Fig). Consistent with these effects on the tumor micro-
environment, metformin reduced the incidence of mesenteric peritoneal and retroperitoneal
wall metastasis metastasis (percentage of mice affected) (Fig 5D) as well as the average number
of metastasis per mouse (Fig 5E). These effects were particularly evident in the more metastatic
model PAN02, although similar trends were obtained for the less metastatic AK4.4 model.
Effects of metformin on desmoplasia are independent of global
metabolic effects
As expected, metformin reduced systemic levels of glucose and Insulin/IGF-I in the PAN02
model (S9Ai–S9Aiii Fig), with similar trends occurring for Insulin levels in the AK4.4 model
(S9B Fig). At the tumor level, metformin induced a trend for reduced activation and phosphor-
ylation of the insulin-like growth factor receptor-1 (IGFR-1) and downstream mediator insulin
receptor substrate 1 (IRS-1) (S9Ci and S9Cii Fig). In addition, activation of ACC was increased
by metformin, with similar trends for AMPKα and AMPKß (S9Ci and S9Cii Fig). However,
metformin did not affect the activation of metabolic pathways in AK4.4 tumors (S9Ci and
S9Ciii Fig), where it more dramatically improved the tumor microenvironment. In addition,
the expression of the autophagy marker L3CB was unchanged by metformin in both models
(S9Ci–S9Ciii Fig). Furthermore, no change in body weight was observed in either model (S10
Fig). These data suggests that the effects of metformin on desmoplasia and metastasis do not
correlate with global activation of metabolic pathways or body weight. On the other hand, as
metformin on the gene expression (qPCR) of M1 (i) and M2 (ii) markers in TAMs isolated from PAN02 tumors in vivo (n = 3). Metformin treatment reduced
expression of the M2markers Arg-1 and IL-10 in TAMs in vivo. (D) Representative Western blots for the expression of signaling proteins in RAW 264.7 cells
treated with metformin at 0, 0.05, 0.1, 0.2 and 0.4 mM. Metformin decreases the activation of signaling pathways and increased activation of AMPKα on RAW
cells. Densitometric analysis of protein expression normalized to ß-actin or total protein (in the case of phosphorylated protein) is depicted as numbers below
the representative bands. (E) Effect of metformin on the protein expression of major cytokines in AK4.4 tumors (n = 4–5) using multiplex protein array.
Metformin treatment associated with reduced IL-1ß and CXCL1 expression in tumors. Data are presented as mean ± standard error in A, C and E. * p < 0.05,
** p < 0.01 vs. control.
doi:10.1371/journal.pone.0141392.g004
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Fig 5. Metformin reduces ECM remodeling, EMT, andmetastasis in a PDACmousemodel. (A)
Expression of genes associated with extra-cellular matrix (ECM) remodeling, epithelial-to-mesenchymal
transition (EMT) and inflammation in AK4.4 tumors from control and metformin-treated mice. Data normalized
to control group. 3–4 samples per group pooled in one single PCR array plate. Metformin reduces the
expression of pro-tumor genes and increases the expression of anti-tumor genes. (B-i) Representative
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shown above, metformin induced specific changes in metabolic pathways in TAMs. Taken
together, our findings indicate that a global change in the activity of metabolic pathways in
tumors does not correlate with the effects of metformin on tumor desmoplasia.
Discussion
Metformin improves cancer outcomes in preclinical models of PDAC [25, 26] and diabetic
patients with pancreatic cancer [32, 35] though the underlying mechanisms are not well under-
stood. Hence, there is a need to continue to study and elucidate the mechanisms of action of
metformin in PDACs. Fibrosis and inflammation are critical components of the desmoplasia
that characterize PDACs [73]. We and others have previously shown that reprogramming the
central instigator of the desmoplastic microenvironment—PSCs—can be an effective interven-
tion in the treatment of PDACs [43, 61, 74]. Furthermore, metastases in PDACs are facilitated
by the active desmoplastic fibro-inflammatory microenvironment that promotes ECM remod-
eling, EMT and tumor invasion [43–45, 75]. We uncovered in this study a previously unknown
role of metformin on the activity of PSCs, TAMs, tumor fibrosis and inflammation, and how it
impacts systemic dissemination of the disease. We found that in overweight and obese patients
—which appear to have increased levels of ECM components in tumors -, metformin treatment
reduced tumor levels of HA. We confirmed that metformin robustly affected HA as well as col-
lagen-I, though to a lesser extent, in preclinical obese/diabetic mouse models of syngeneic
PDACs. Furthermore, we found that the alleviation of desmoplasia occurred due to a direct
effect on HA and collagen-I production by PSCs, which was associated with a reduction of
AT1/PDGF-ß expression and TGF-ß/SMAD-2 signaling. Although the precise mechanisms
for the preferential effect of metformin on HA over collagen-I in all preclinical models and
human cancer patients studied so far are not clear, it is an intriguing and potentially important
finding. Nonetheless, we have recently observed that HA plays an equally important role as col-
lagen-I in reducing therapy delivery and efficacy in PDACs [43, 76].
In addition to reducing fibrosis, we found here that metformin reduces the production of
pro-metastatic cytokines. In both tumor models, metformin reduced the secretion of IL-1ß,
which has been shown to promote metastasis in a PDAC model [30]. IL-1β in tumors is typi-
cally produced by PSCs, inflammatory and tumor cells, is involved in macrophage recruitment
and PSC activation, and both IL-1β and CXCL1 worsen desmoplasia [77–80]. Consistently, it
has been shown that IL-1βmediates at least in part the effects of metformin on the malignant
transformation of mammary epithelial cells [81]. Furthermore, we found that metformin
reduced the levels of chemokines involved in TAM recruitment and function (e.g. CSFs, CCL3)
[82–84], and consistently, metformin reduced the recruitment of TAMs and their expression
of M2 markers in vivo and in vitro at clinically relevant doses. Our data corroborate the previ-
ous findings of Karnevi et al showing that metformin shifts macrophage polarization in vitro
Western blots showing the effect of metformin (300 mg/Kg) on MMPs and EMTmarkers in AK4.4 tumors. (B-
ii) Densitometric analysis of protein expression normalized to ß-actin. Metformin decreases the expression of
MMP-9 and vimentin and increases the expression of e-cadherin in AK4.4 tumors. (C) MMP activity in AK4.4
tumor protein extracts from control and metformin-treated mice (n = 3–4). Metformin decreases the activity of
MMPs. (D) Effect of metformin on the percentage of mice affected (incidence) with mesenteric (peritoneal)
and abdominal wall (retroperitoneal) metastasis in AK4.4 and PAN02 models (n = 3–8). Metformin reduced
the percentage of mice that develop wall metastasis in the more metastatic model (PAN02 model) and
induced a tendency for reduced wall as well as mesenteric metastasis in the less metastatic AK4.4 model. (E)
Effect of metformin on the number (average) of mesenteric (peritoneal) and abdominal wall (retroperitoneal)
metastasis per mouse in the AK4.4 and PAN02 models (n = 3–8). Metformin reduced the number of wall
metastasis in the PAN02 model. There were also trends for fewer mesenteric metastasis in AK4.4 and
PAN02 tumors. Data in B, C and E are presented as the mean ± standard error. *p < 0.05 vs. control.
doi:10.1371/journal.pone.0141392.g005
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[17]. STAT3 promotes polarization of TAMs to an M2 phenotype [85], and It has been shown
that STAT3 activity is decreased by metformin [81] in part via activation of AMPKα in multi-
ple cell types [70, 86]. We found here that the effects of metformin on macrophage polarization
associated with activation of AMPKα/ACC and reduction of STAT3 signaling.
Activated PSCs and M2 TAMs have been shown to promote ECM remodeling and EMT
[87, 88]. Here we found that, consistent with the effects on these cells, metformin reduces ECM
remodeling and EMT. This is also in line with a recent report describing the modulation of
EMT by metformin in the PAN02 model [89], and with the finding that metformin impeded
TGF-ß-promoted EMT in breast cancer cells [90]. Importantly, ECM remodeling and EMT
have been shown to promote tumor invasion and metastasis [43–45, 75], and as expected we
observed a decrease in metastasis in mice treated with metformin.
The modulation of systemic and local metabolism has been the major focus of studies evalu-
ating the effect of metformin in PDAC. Metformin could improve systemic levels of Insulin/
IGF-1 and glucose, and affect Insulin/IGF-1 signaling and AMPK/ACC activation. However,
we found that this only occurred (and mildly) in one of the models (PAN02). This suggests
that the effects of metformin on desmoplasia do not correlate with global activity of metabolic
pathways. In fact, despite earlier reports suggesting that IGF-I may be involved in cancer risk
and outcome [91], subsequent clinical studies failed to establish anti-IGF-I agents as cancer
therapeutics [92]. In addition, there is no convincing evidence for a carcinogenic role of any
insulin derivative currently used in therapy for diabetes [93]. Similarly, the beneficial effects of
metformin did not correlate with levels of blood sugar in patients [33], and in a pre-clinical
model Franco and colleagues have shown that the effects of metformin may be more dependent
on the direct effect on tumors rather than on systemic metabolism [94]. In addition, despite
the report that autophagy can be affected by metformin to reduce tumor progression [95, 96],
we found no evidence of this in our study. Of note, metformin did not affect body weight
through the experiment (S10 Fig), suggesting a body weight-independent effect on tumor
growth.
Importantly, two very recent studies—one retrospective [97] and the first prospective study
[98] indicated that metformin might not be uniformly beneficial. The benefit in some but not
all studies suggests that a subset of tumors may not respond to metformin and that a careful
selection of patients may be required for metformin to be effective. We found that metformin’s
effect on desmoplasia in patients only occurred when their BMI was higher than 25 (over-
weight and obese patients). This indicates that metformin may not be beneficial in normal
weight patients, and suggests that BMI should be explored as a potential biomarker of response
to this drug.
Conclusion
In conclusion, this study indicates that in an overweight/obese condition, metformin repro-
grams the fibro-inflammatory tumor microenvironment and ultimately reduces metastasis.
We found that metformin directly reduces AT1/PDGF-ß and TGF-ß signaling and ECM pro-
duction by PSCs—preferentially HA. Metformin also reduces inflammation—another key ele-
ment of desmoplasia—through reduction of cytokine production, and recruitment and
M2-polarization of TAMs. This was associated with AMPK activation and STAT3 signaling
inhibition in macrophages. Finally, the alleviation of desmoplasia by metformin was associated
with reduced ECM remodeling, EMT and systemic metastasis (Fig 6). Importantly, the effects
on desmoplasia observed in human samples seem restricted to an overweight/obese popula-
tion, which appear to have tumors with increased content of ECM components. With nearly
200 trials ongoing to address the effect of metformin on diabetic and non-diabetic cancer
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patients, understanding the yet elusive mechanisms of action of metformin may provide an
opportunity to uncover potential biomarkers of response and define strategies of patient strati-
fication for the judicious use of this highly promising yet generic drug.
Supporting Information
S1 Fig. Metformin treatment does not reduce collagen-I levels in human pancreatic can-
cers. Effect of metformin on tumor collagen-I levels in normal weight [Body mass index
(BMI)<25)] or overweight/obese patients (BMI>25). (i) Immunohistochemical analysis of
total tumor collagen-I levels. Metformin treatment does not alter tumor collagen-I-positive
area fraction (%) (n = 23 controls, 6 metformin). Data are presented as the mean ± standard
error.
(EPS)
S2 Fig. Metformin reduces density of ECM producing PSCs in PAN02 tumors. (i) Represen-
tative immunohistochemistry images showing the effects of metformin on α-SMA, hyaluronan
and collagen-I levels in PAN02 tumors. (ii) Immunohistochemical analysis of total α-SMA/
hyaluronan double positive cells. Metformin induced a tendency for decreased area fraction
(%) of hyaluronan-positive activated PSCs (n = 5–6). (iii) Immunohistochemical analysis of
total α-SMA/collagen-I double positive cells. Metformin decreases the area fraction (%) of col-
lagen-I-positive activated PSCs (n = 5–6). Data are presented as the mean ± standard error.
p< 0.05 vs. control.
(EPS)
S3 Fig. High doses of metformin reduce the viability of PSCs in vitro. Effect of metformin
on human PSC viability. PSCs were incubated with metformin at increasing doses for 48 h, and
MTT viability assay was performed. At high doses (>7.5mM), metformin significantly reduces
cell viability. Values are the mean ± standard error. p< 0.05, p< 0.01, p< 0.001 vs.
Fig 6. Metformin reprograms pancreatic stellate cells (PSCS) and tumor-associated macrophages (TAMs), alleviates the fibro-inflammatory tumor
microenvironment and reducesmetastasis.Metformin treatment reduces collagen-I and HA production by PSCs, leading to decreased fibrosis in PDACs.
Metformin treatment also reduces cytokine production, infiltration and M2 polarization of TAMs, leading to decreased inflammation. This associated with
improved desmoplasia and reduced extracellular matrix (ECM) remodeling, epithelial-to-mesenchymal transition (EMT), and metastasis.
doi:10.1371/journal.pone.0141392.g006
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untreated control.
(EPS)
S4 Fig. Metformin reduces pSTAT3 expression in PDACs. (i) Representative blots showing
the effect of metformin on phospho and total p38, STAT3, JNK and NFKB expression in
AK4.4 and PAN02 tumors. ß-actin is used as a control for protein loading. (ii) Densitometric
analysis of protein expression normalized to total levels of the protein of interest. Metformin
decreases the expression of p-STAT3 in both tumor models. Data are presented as the
mean ± standard error.  p< 0.05 vs. control.
(EPS)
S5 Fig. Metformin reduces inflammation in a second PDACmouse model (PAN02) and
additional gene expression data on AK4.4 model. (A) Effect of metformin on the levels of
CD45(+)CD11b(+)F4/80(+) TAMs in PAN02 tumors (percentage of total viable cells as
assessed by flow cytometry) (n = 4–7). We observed a tendency for reduced numbers of TAMs
with metformin. (B) Effect of metformin on the protein expression of major cytokines in the
PAN02 tumor model. Metformin treatment associates with reduced IL-1ß expression in
tumors (i) and plasma (ii) (n = 6–7). (C) Expression of genes associated with inflammation in
AK4.4 tumors from control and metformin-treated mice. Data normalized to control
group. 3–4 samples per group pooled in one single PCR array plate. Metformin reduces the
expression of pro-tumor genes and increases the expression of anti-tumor genes. Data are pre-
sented in A and B as the mean ± standard error. p< 0.05 vs. control.
(EPS)
S6 Fig. Metformin reduces the viability of macrophages in vitro. Effect of metformin on
macrophage viability in vitro. Macrophages were incubated with metformin at increasing doses
for 48 h, and MTT viability assay was performed. At doses> 0.2mMmetformin significantly
reduces cell viability. Data are presented as the mean ± standard error.  p< 0.05,  p< 0.01
vs. untreated control.
(EPS)
S7 Fig. Additional metabolic effects of metformin on macrophages in vitro. Representative
Western blots for the expression of additional metabolic markers (AMPK-ß and ACC) on
RAW 264.7 (mouse leukaemic monocyte-macrophage) cells treated with metformin at 0, 0.05,
0.1, 0.2 and 0.4 mM. Metformin increased the activation of ACC when serum was present in
the media. Densitometric analysis of protein expression normalized to total protein is depicted
as numbers below the representative bands.
(EPS)
S8 Fig. Effects of metformin on ECM remodeling and EMT in a second PDAC mouse
model (PAN02) and in vitro. (A) Expression of genes associated with ECM remodeling, EMT
and inflammation in PAN02 tumors from control and metformin-treated mice. Data normal-
ized to control group. 3–4 samples per group pooled in one single PCR array plate. Metformin
reduces the expression of MMPs and increases the expression of Timp-4. (B-i) Representative
blots showing the effect of metformin on MMPs and epithelial-to-mesenchymal transition
(EMT) markers in PAN02 tumors. ß-actin is used as a control for protein loading. (B-ii) Densi-
tometric analysis of protein expression normalized to ß-actin. Metformin induced a tendency
for decreased MMP-2 and vimentin in PAN02 tumors. (C) Representative Western blot for the
expression of MMP-9 on PSCs treated with metformin at 0, 0.1, 1 and 10mM (in vitro). Met-
formin decreased expression of MMP-9. Densitometric analysis of protein expression normal-
ized to total protein is depicted as numbers below the representative bands. Data in B are
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presented as the mean ± standard error.
(EPS)
S9 Fig. The metabolic effects of metformin are not present in both PDACmouse models.
(Ai-iii) Effects of metformin on systemic levels of glucose (i), insulin (ii) and insulin-like
growth factor-I (IGF-I) in PAN02 tumor bearing mice (iii) (n = 7–8). Metformin reduces levels
of glucose, insulin and induced a trend for reduced levels of IGF-I in circulation. (B) Effects of
metformin on systemic levels of insulin in AK4.4 tumor bearing mice (iii) (n = 8) Metformin
induced a trend for reduced levels of Insulin in circulation. (C-i) Representative blots showing
the effect of metformin on metabolic markers in PAN02 and AK4.4 tumors. ß-actin is used as
a control for protein loading. (C-ii) Densitometric analysis of protein expression normalized to
total protein or ß-actin in the case of LC3B. Metformin decreases the expression of p-IRS-1
and increased the expression of p-AMPK-β and p-ACC in PAN02 but not in Ak4.4 tumors.
Data are presented as the mean ± standard error. p< 0.05, p< 0.01 vs control.
(EPS)
S10 Fig. Metformin does not affect body weight in tumor-bearing animals. Effect of metfor-
min on body weight after tumor implantation (n = 4–10). Metformin does not affect body
weight in tumor-bearing mice. Data are presented as the mean ± standard error.
(EPS)
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